Aussie Immutep at near 1-year high on positive data from cancer therapy study

Immutep

18/05/2023 05:37

** ASX-listed shares of Immutep Ltd  IMM.AX  jump as much as
55.5% to A$0.42, their highest since June 
    ** Biotech firm says its lead candidate eftilagimod in
combination with Merck & Co. Inc's  MRK.N  Keytruda prolonged
the lives of patients with non-small cell lung cancer in a
mid-stage study
    ** IMM plans to release more data on the study later this
year
    ** Earlier this week, co received positive feedback from the
U.S. Food and Drug Administration (FDA) for late-stage clinical
development of eftilagimod alpha 
    ** Stock has risen ~53% this year, as of last close

 (Reporting by Mehr Bedi in Bengaluru)
 ((Mehr.bedi@thomsonreuters.com))